Ethyl pyruvate (EP) has been shown to have significant anti-inflammatory activities. Here, we explore the therapeutic effects of EP administration on tumor growth and metastasis in orthotopic implantation human gastric cancer models in severe combined immunodeficiency (SCID) mice. After SCID mice were treated with EP, the tumor growth and liver metastasis from gastric cancer were investigated and its possible molecular mechanisms were further studied. As a result, it was found that EP could inhibit tumor growth and liver metastasis of gastric cancer, and reduce tumor Iymphangiogenesis indicated by lymphatic microvessel density (LVD) in gastric cancer and metastatic liver tumor. Also, EP decreased the expression of high mobility group box-Bl (HMGBl), receptor for advanced glycation endproducts (RAGE), vascular endothelial growth factor (VEGF) and membrane type-l matrix metalloprotease (MTI-MMP) in gastric cancer and metastatic liver tumor, but it exerted no effect on expression of nuclear factor-kappa B (NF-KB). Taken together, we suggest that the new application of EP could be a therapeutic option in the treatment of gastric cancer and metastatic liver tumor.
Gastric cancer is one of the most common malignancies worldwide, with an estimated 934,000 cases reported globally in 2002, and is the second most common cause ofdeath from cancer (I). Gastric cancer is also a genetic disease developing from a multi-step process. Single or multiple mutations in genes related to growth control, invasion and metastasis form the molecular genetic basis of malignant transformation and tumor progression (2) . Mounting evidence suggests that HMGB 1-RAGE-NF-KB pathway may playa crucial role in the development and progression of many malignant tumors.
Receptor for advanced glycation endproducts (RAGE) is a multiligand cell surface receptor of the immunoglobulin superfamily and a newly recognized invasion-related gene. HMGB-l is an evolutionarily ancient and critical regulator of cell death and survival binding to RAGE. The interaction between RAGE and HMGB-l could be closely associated with tumor metastasis (3) . HMGB 1 is a proinflammatory cytokine involved in tumor angiogenesis and metastasis, and may be a useful serological biomarker for early diagnosis and prognosis of gastric cancer (4, 5) . RAGE, the cellular receptor identified for extracellular HMGB I, is associated with tumorigenesis and growth of gastric, esophageal, lung and colorectal cancer (6) (7) (8) (9) . HMGBI and RAGE are also expressed in hepatocellular and colorectal carcinomas, and contribute to tumor development (10, II). NF-KB activation frequently observed in gastric cancer is a valuable prognostic variable, and inhibition of the NF-KB pathway suppresses peritoneal dissemination of gastric cancer (12, 13) . Thus, blockade of the HMGB I-RAGE-NF-KB pathway through some strategies may be a potential therapeutic option for the treatment of cancer.
Pyruvate has been shown to display antiinflammatory and antioxidant properties. EP, a stable lipophilic pyruvate derivative, attenuates activation of the p38 mitogen-activated protein kinase and NF-KB signaling pathways. Pretreatment with EP prevents endotoxin lethality, inhibits the release of HMGB I and ameliorates murine colitis and renal ischemia and reperfusion injury (14, 15) . Delayed treatment with EP suppresses tumor growth through decrease of innate and adaptive immune cell infiltrates in the liver (16) . Necrosis-to-apoptosis switch activity of EP could contribute to its anti-inflammatory action and suppress tumor development (17) .
Therefore, as a low-cost and anti-inflammatory agent, EP-induced antitumor effects need to be further explored. In the present study, we established a SCID mouse orthotopic implantation gastric cancer model and investigated the therapeutic effects of EP on tumor growth and metastasis. We hypothesized that EP could suppress tumor growth and metastasis through regulation of the HMGB I-RAGE-NF-KB pathway.
MATERIALS AND METHODS

Materials
Six-week-old female scm mice were purchased from Shanghai laboratory animal Center of Chinese Academy Sciences (SPF, NO.SCXK033). The primers of HMGBl, RAGE, NF-KB, VEGF and MTl-MMP were synthesized by ABI Co., Ltd (USA). All antibodies were from Santa Cruz Biotechnology, Ltd (Santa Cruz, CA, USA).
Drugs and reagents
Ethyl pyruvate was obtained from Sigma-Aldrich (St. Louis, MO, USA). M-MLV Reverse Transcriptase was from Promega (Madison, WI, USA); SYBR Green Master Mixture was from Takara (Otsu, Japan); RNase A was from KeyGEN biology (Nanjing, China).
Construction of SCID mouse orthotopic implantation gastric cancer model
Human gastric cancer SGC-790 1 cell line was originally derived from a primary tumor and maintained by passage in the subcutis of nude mice. Animal models were made using orthotopic implantation of histological intact tissue of human gastric carcinoma. Tumors were resected aseptically. Necrotic tissues were cut and the remaining healthy tumor tissues were scissor minced into pieces (about 2 mm x 2 mm in diameter) in Hank's balanced salt solution. Each tumor piece was weighed and adjusted to 50 mg. Mice were anesthetized with 4.3% trichloraldehyde hydrate. An incision was made through the left upper abdominal pararectal line. Then the peritoneal cavity was carefully exposed and a part of the serosa membrane in the middle of the greater curvature of the stomach was mechanically injured using scissors. A tumor piece was fixed on each injured site of the serosal surface. The stomach was returned to the peritoneal cavity, and the abdominal wall and skin were closed. After 7 days, mice were randomly separated into three groups with six mice per group and they were injected i.p. with 40-80mg/kg EP once a day. Control mice were injected with the same amount of PBS. After three weeks, mice were sacrificed by cervical dislocation. The tumor volume was measured with a caliper, using the formula volume = (length x width") / 2. Samples of the tumor were immediately frozen in liquid nitrogen for later use.
FQ-PCR
Total RNA was extracted from frozen samples. Isolated RNA was electrophoresed through 1.0% agaroseformaldehyde gels to verify RNA quality. First strand cDNA was generated from 1 ug of total RNA in a final volume of20 III using SuperScript II (Life Technologies) and oligo (dT) primers. Amplification was carried out in a volume of 50 III mixture, containing 0.5 III of each primer (25Ilmol/L), 0.5 ul dNTPs (IOmmoIlL), lU ofTaq DNA polymerase, 10 III of 5x PCR buffer (with Mg2+, 25mmoIlL), 5111 ofcDNA templates and 0.5111 fluorescent probe, and then made up to a volume of50 III with deionized water. The PCR primer sequences were as follows: HMGB 1, 5' -ATATGGCAAAAGCGGACAAG-3' and 5'-AGGCCAGGATGTTCTCCTTT-3'; RAGE, 5'-GTCATGGAACTGCCCAAACT-3' and 5'-TCCTTCTGCGGATCTGTCTT-3'; NF-KB, 5'-CTGGCTGGTATCTGTGGTCA-3' and 5'-AACCAAACGCAATCGTCACT-3'; VEGF, 5' -AGGCCAGCACATAGGAGAGA-3' and 5'-TTTCCCTTTCCTCGAACTGA-3';
MTl-MMP, 5'-GACAGTCTGGCCACTGTCAA-3' and 5'-TGGGGAGGAAAGGGAATAGT-3'; GAPOH, 5'-CAACGAATTTGGCTACAGCA-3' and 5'-AGGGGTCTACATGGCAACTG-3'. The FQ-PCR amplification was accomplished as follows: an initial denaturation at 93°C for 2 min was followed by 10 cycles of denaturation at 93°C for 45 sec, annealing at 55°C for 60 sec, and extension at 93°C for 45 sec followed by 30 cycles. Finally, an additional extension was achieved for I min at 55°C. To normalize the data, GAPOH was chosen as an endogenous control. The comparative L::.Ct value was used to determine gene copy numbers.
Immunohistochemistry staining
Immunohistochemical staining was performed using the streptavidin-peroxidase technique. Paraffin-embedded tissues were cut into 4 urn thick sections and placed on saline coated slides. After deparaffinization, antigen retrieval was performed by immersing the sections in 10 mM citrate buffer (pH 6.0) and heating twice in a microwave oven (95°C) for 5 min each time. Endogenous peroxidase activity was blocked by incubation with 1% hydrogen peroxide in distilled water for 10 min. Tissue sections were incubated with normal donkey serum for 20 min at room temperature and then incubated with primary antibodies against HMGBI, RAGE, NF-KB, VEGF and MTl-MMP for 2 h at room temperature. Bound antibodies were detected with secondary antibody and streptavidin-peroxidase complex, using diaminobenzidine tetrahydrochloride as the substrate. The sections were counterstained with hematoxylin.
Quantitation ofimmunohistochemistry
For intratumoral LVO assessment, we first identified the area containing the 02-40 positive vessels by scanning the sections at low magnification (40x). Then, we counted the number of positive vessels in three high magnification fields (200x). Single immunoreactive endothelial cells, or endothelial cell clusters separate from other microvessels, were counted as a vessel. The mean visual microvessel density for 02-40 was calculated as the average of five counts.
Statistical analysis
The results obtained were expressed as the mean ± standard error from at least three independent experiments. One-way analysis of variance (ANOVA) was used to analyze the differences between groups. The LSD method of multiple comparisons was used when the probability for ANOVA was statistically significant. Statistical significance was P<0.05.
RESULTS
Effects ofEP on tumor growth and liver metastasis
To explore the therapeutic effects of EP on tumor growth and metastasis, we established SCID mouse orthotopic implantation gastric cancer models. After mice were treated with EP, the average volume and weight of gastric cancer in the EP treatment groups were significantly smaller than those of the control group (Fig. I, A-B ). In addition, the number of metastatic liver tumor nodules from gastric cancer and the average weight of livers in EP treatment groups were also significantly smaller than those of the control group (Fig. I, C-D) . . (A, B) The average volume and weight ofgastric cancer in EP treatme nt groups were significantly smaller than those ofthe control group (**P <O.Ol). C, D) The number ofmetastatic liver tumor nodules fro m gastric cancer and the average weight of livers in EP treatment groups were significantly sma ller than those of the control group (*P<O.05, **P<O.OI).
Fig. 2. Effects ofEP on expression ofHMGB 1, RAGE, NF-KB, VEGF and MT I-MMP protein in gastric cancer and metastatic liver tumor (x200) . The protein exp ression ofHMGBl , RAGE. VEGF and MTI-MMP were lower in EP treatment
groups than the control group in gastric cancer and metastatic liver tumor. But, there was no significant difference for NF-KB protein expression between EP treatment groups and the control group.
Effects ofEP on expression ofHMGBl , RAGE, NF-KB, VEGF and MTl-MMP mRNA
To study the molecular mechanisms of EP on tumor growth and metastasis, we detected the mRNA expression levels of HMGBI , RAGE, NF-KB, VEGF and MTl-MMP by FQ-PCR in gastric cancer and metastatic liver tumor. As a result, the mRNAexpression levels ofHMGBI , RAGE, VEGF and MTl-MMP were lower in EP treatment groups than the control group respectively in gastric cancer and metastatic liver tumor. However, there was no significant difference for NF-KB mRNA expression between treatment groups and the control group (Table I) .
Effects ofEP on expression ofHMGBl, RAGE, NF-KB, VEGF and MTl-MMP protein
We further detected the protein expression levels of HMGBI, RAGE, NF-KB, VEGF and MTl-' MMP by immunohistochemistry in gastric cancer, and metastatic liver tumor. As shown in Fig. 2 and Table II , the protein expression levels of HMGB 1, RAGE, VEGF and MTl-MMP were lower in the EP treatment groups than the control group in gastric Gastric cancer Mtlastat ic Hver tumor Fig. 3 . Effects ofEP on LVD in gastric cancer and metastatic liver tumor (x200). The LVD counts in EP treatment groups were significantly lower than that ofthe control group in gastric cancer and metastatic liver tumor.
cancer and metastatic liver tumor. But, there was no significant difference for NF-KB protein expression between the treatment groups and the control group.
Effects ofEP on LVD in gastric cancer and metastatic liver tumor
Tumor lymphangiogenesis was determined by 02-40 microvessel counts. As shown in Fig. 3 and Table III , the LVO counts in EP treatment groups were significantly lower than that of the control group in gastric cancer and metastatic liver tumor.
DISCUSSION
HMGBI-RAGE-NF-KB pathway is closely associated with tumorigenesis, growth and metastasis of many cancers. Recent studies have shown that HMGB 1 is critical for the survival oftumor cells, and targeted knockdown of HMGB 1 can inhibit tumor growth and metastasis (18) . RAGE, as a multiligand receptor, affects the characteristic differences of various cancer cells. Cromolyn binds SlOOP, prevents activation of RAGE, inhibits tumor growth and increases the effectiveness of gemcitabine in experimental models. MAbGB3.1 administration also markedly reduces tumorigenesis in the mouse model of colitis-associated cancer (19, 20) . NF-KB pathway controls transcriptional activation of genes important for tight regulation of many cellular processes and is aberrantly expressed in many types of cancer. Inhibition of the NF-KB pathway can reduce tumor growth and viability (21) . Thus, blockade of the HMGBI-RAGE-NF-KB pathway through some strategies could result in attenuation of tumor development and growth.
In the present study, it was found that EP inhibited the growth and liver metastasis of gastric cancer, decreased the expression of HMGB I and RAGE, and suppressed tumor lymphangiogenesis in gastric cancer and metastatic liver tumor in SCIO mouse gastric cancer models, suggesting that EP might inhibit tumor growth and metastasis through down-regulation of the HMGBI-RAGE pathway. In fact, some studies have displayed the role of EP in treatment of some diseases such as infection/sepsis and injury including ischemia-reperfusion through regulation of the HMGBI-RAGE pathway (22) .
VEGF and MTl-MMP are important molecules involved in tumor metastasis. The expression of VEGF is correlated with tumor angiogenesis, differentiation degree and lymphatic metastasis (23) . Oownregulation ofVEGF expression inhibits tumor proliferation and vascular permeability, representing a mechanism for antitumor activity (24) . MTl-MMP expressed on the tumor cell surface activates pro-MMP to exacerbate the malignancy and could be a powerful indicator of distant metastasis of gastric cancer. Specific downregulation of MTl-MMP expression causes significant inhibition of the migration and invasion oftumor cells, and anti-MTl-MMP mAb is a promising probe for future diagnosis oftumors by nuclear medical imaging (25, 26) . In our study, EP inhibited growth and metastasis of gastric cancer and decreased the expression of VEGF and MTl-MMP, suggesting that EP might inhibit tumor growth and metastasis through downregulation of VEGF and MTl-MMP expression. Some data show that activation of the HMGB1-RAGE pathway contributes to the increase ofVEGF and MTl-MMP expression (27) (28) (29) . Thus, HMGB1-RAGE pathway might mediate EP-induced down-regulation of VEGF and MTl-MMP expression and involve in tumor growth and metastasis.
In conclusion, we suggest that the new application of EP could be a therapeutic option in the treatment of gastric cancer and metastatic liver tumor in SCID mouse orthotopic implantation tumor models. More importantly, EP has been tested in Phase II trials of high-risk cardiac patients undergoing cardiopulmonary bypass and has shown to be safe and well-tolerated (30) . Although there was no benefit conferred to these patients, EP has not been tested in the cancer setting in humans, an area that appears promising for clinical testing.
